Compare FOCL & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOCL | ANIK |
|---|---|---|
| Founded | N/A | 1983 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 200.9M |
| IPO Year | 1998 | 1996 |
| Metric | FOCL | ANIK |
|---|---|---|
| Price | $4.20 | $21.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 199.0K | 100.9K |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | N/A | ★ N/A |
| Revenue | $70,527,000.00 | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.63 | N/A |
| 52 Week Low | $4.01 | $8.56 |
| 52 Week High | $6.40 | $22.88 |
| Indicator | FOCL | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 56.38 |
| Support Level | $4.01 | $20.13 |
| Resistance Level | $4.50 | $22.70 |
| Average True Range (ATR) | 0.19 | 0.89 |
| MACD | 0.02 | -0.25 |
| Stochastic Oscillator | 58.16 | 40.29 |
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.